Quick Answer
Black Diamond Therapeutics, Inc. reported Stockholders Equity of $112.21 million for fiscal year 2025.
Black Diamond Therapeutics, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $112.21M | +34.7% |
| 2024 | $83.28M | -28.7% |
| 2023 | $116.74M | +0.9% |
| 2022 | $115.69M | -40.9% |
| 2021 | $195.90M | -36.3% |
| 2020 | $307.76M | +752.6% |
| 2019 | -$47.16M | -203.4% |
| 2018 | -$15.54M | -132.8% |
| 2017 | -$6.67M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $126.15M | +29.5% | -4.9% |
| June 30, 2025 | $132.61M | +20.0% | -6.3% |
| March 31, 2025 | $141.52M | +35.7% | +69.9% |
| December 31, 2024 | $83.28M | -28.7% | -14.5% |
| September 30, 2024 | $97.43M | -27.5% | -11.8% |
| June 30, 2024 | $110.52M | +34.5% | +6.0% |
| March 31, 2024 | $104.31M | +6.2% | -10.6% |
| December 31, 2023 | $116.74M | +0.9% | -13.1% |
- Black Diamond Therapeutics, Inc. showed an increase of +34.7% in Stockholders Equity compared to the prior fiscal year.
- Over the 2017–2025 period, Black Diamond Therapeutics, Inc.’s stockholders equity has grown by 1781.1% (from -$6.67 million to $112.21 million).
- The most recent figure is from Black Diamond Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 16, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: